ANSWER: B

Rationale:

Glucocorticoid-induced osteoporosis (GIOP) is not defined by reaching a T-score of −2.5; it is an indication-based decision driven by corticosteroid dose and duration. ACR guidelines recommend initiating bisphosphonate prophylaxis for any patient on prednisone ≥2.5 mg/day for ≥3 months — a threshold this patient met approximately 11 months ago at prednisone 20 mg/day. The DEXA results showing T-scores of −1.8 and −1.4 confirm that bone loss has already begun (osteopenia range), reinforcing the urgency of anti-resorptive therapy. Waiting for T-score to reach −2.5 (the WHO diagnostic threshold for osteoporosis) before treating represents a failure of preventive care in the glucocorticoid context — by that point, substantial bone loss has already occurred. Alendronate 70 mg weekly or risedronate 35 mg weekly are first-line oral agents for GIOP prophylaxis, alongside continuation of calcium and vitamin D supplementation.

• Option A: Option A is incorrect because the ACR bisphosphonate initiation threshold in GIOP is based on corticosteroid exposure (dose and duration), not on T-score; the T-score of −2.5 is the WHO diagnostic threshold for general osteoporosis and is not the trigger for bisphosphonate initiation in the glucocorticoid-treated patient.
• Option C: Option C is incorrect because bisphosphonates are not contraindicated in vitamin D deficiency; however, hypocalcemia is a concern, which is why calcium and vitamin D supplementation are recommended alongside bisphosphonates — not as a prerequisite before starting them. Checking 25-hydroxyvitamin D is reasonable but should not delay bisphosphonate initiation given her established GIOP risk.
• Option D: Option D is incorrect because teriparatide is reserved for patients with very severe GIOP (very low T-scores, multiple fractures) or those who have failed bisphosphonate therapy; it is not first-line for all patients with GIOP, and bisphosphonates remain the established initial pharmacotherapy for prevention and early treatment of GIOP.

ANSWER: A

Rationale:

This is a classic presentation of avascular necrosis (AVN) following corticosteroid therapy: progressive unilateral hip pain in a patient who received prolonged high-dose corticosteroids, with a normal plain radiograph. AVN is a well-recognized class effect of corticosteroid therapy with no established safe minimum dose — it has been reported after short high-dose pulse courses as well as prolonged therapy. The mechanism is corticosteroid-induced adipocyte hypertrophy in subchondral bone marrow increasing intraosseous pressure, combined with direct endothelial injury to terminal arterioles, producing ischemic necrosis. The femoral head is the most common site. The defining clinical pearl is that plain radiographs are characteristically normal in early AVN because the initial pathological changes are in the marrow vasculature, not yet producing the cortical collapse, flattening, or sclerosis visible on plain films. MRI is the gold standard for early AVN diagnosis, with sensitivity exceeding 90%; it demonstrates subchondral marrow edema and the characteristic double-line sign at the reactive interface. Early diagnosis is essential because core decompression can preserve the femoral head if performed before subchondral collapse.

• Option B: Option B is incorrect because a normal plain radiograph does not exclude stress fracture in high-risk patients, but the clinical picture — progressive aching hip pain over months in a patient with known high corticosteroid exposure — is more consistent with AVN than stress fracture. More importantly, MRI is more sensitive than bone scan for early AVN and should be ordered first.
• Option C: Option C is incorrect because the duration (three months), progressive weight-bearing nature, and specific context of high-dose corticosteroid use make bursitis a far less likely explanation than AVN; ultrasound for bursitis would be premature.
• Option D: Option D is incorrect because while immunosuppression does increase infection risk, septic arthritis typically presents with fever, joint warmth, erythema, and elevated inflammatory markers, none of which is described here; the clinical picture is far more consistent with AVN than infection.

ANSWER: C

Rationale:

Steroid-induced psychosis is a well-established adverse effect of corticosteroids that characteristically presents within the first one to two weeks of high-dose therapy (prednisone ≥40 mg/day or equivalent), exactly as described here on day six of prednisone 60 mg/day. The mechanism involves glucocorticoid receptor-mediated effects on limbic system circuits and dopaminergic and serotonergic signaling in the prefrontal cortex, producing a clinical picture of acute mania or psychosis — agitation, grandiosity, disorganized thought, and sometimes hallucinations. Corticosteroid-induced psychosis is dose-dependent and has no reliable prior-history predictor; patients with no prior psychiatric illness can develop frank psychosis at high doses. The most important management step is dose reduction to the minimum dose required for disease control. This typically produces resolution within days to weeks. Short-term antipsychotic agents (haloperidol, olanzapine, quetiapine) may be required for immediate management of agitation and disorganization, but they should be used as bridge therapy while the corticosteroid dose is reduced — not as a substitute for addressing the causative agent.

• Option A: Option A is incorrect because the temporal correlation with high-dose prednisone initiation on day six is highly specific for steroid-induced psychosis; neuropsychiatric lupus is possible but should be a diagnosis of exclusion after iatrogenic cause has been considered, and escalating immunosuppression in a patient experiencing a drug-induced psychiatric reaction would be harmful.
• Option B: Option B is incorrect because corticosteroid withdrawal reactions typically present with somatic symptoms (fatigue, myalgia, arthralgia, nausea) rather than acute psychosis, and the patient's dose has been increased rather than withdrawn; there is no paradoxical cholinergic excess mechanism associated with rapid corticosteroid dose escalation.
• Option D: Option D is incorrect because hydroxychloroquine does not cause clinically significant serotonin reuptake inhibition and does not interact with corticosteroids to produce serotonin syndrome; the classic triad of serotonin syndrome (clonus, hyperthermia, diaphoresis) is absent from this presentation.

ANSWER: D

Rationale:

The key pharmacological concern with adding naproxen to a patient already on prednisone 15 mg/day is the well-characterized multiplicative increase in GI toxicity. Corticosteroids impair gastric mucosal defense by inhibiting phospholipase A2 (PLA2) through lipocortin/annexin-A1 induction, reducing arachidonic acid availability for prostaglandin synthesis. NSAIDs independently suppress COX-1-dependent prostaglandin E2 synthesis, the primary mediator of mucus secretion, bicarbonate production, and mucosal blood flow. Together, these complementary mechanisms of prostaglandin suppression produce approximately 15-fold greater peptic ulcer disease and GI bleeding risk compared to either agent alone. If naproxen were used, PPI co-prescription would be mandatory. However, a better choice is available: low-dose colchicine (1.2 mg + 0.6 mg, the AGREE trial-validated regimen) is entirely appropriate at a creatinine clearance of 62 mL/min — dose adjustment for colchicine is required only at eGFR <30 mL/min, and contraindication is at eGFR <15 mL/min. Colchicine avoids the corticosteroid-NSAID GI interaction entirely and has no significant interaction with her current medications. The attack presumably began recently, and colchicine within 36 hours of onset is maximally effective.

• Option A: Option A is incorrect because NSAIDs are not first-line in a patient already on systemic corticosteroids without additional GI protection — prednisone does not protect against NSAID-induced GI mucosal injury; it additively worsens it by suppressing prostaglandin precursor availability.
• Option B: Option B is incorrect because naproxen does not clinically significantly inhibit CYP2C9-mediated prednisolone metabolism at therapeutic doses; the GI interaction, not a pharmacokinetic CYP2C9 interaction, is the clinically relevant concern. Celecoxib, while gentler on the GI mucosa, still has some prostaglandin-suppressing effects and is not the cleanest solution in this patient on corticosteroids.
• Option C: Option C is incorrect because colchicine dose adjustment is required at eGFR <30 mL/min, not at 62 mL/min; this patient's renal function does not preclude standard low-dose colchicine use.

ANSWER: D

Rationale:

This case illustrates one of the most dangerous and underrecognized drug interactions in patients on ritonavir-containing antiretroviral regimens. Ritonavir is an exceptionally potent CYP3A4 inhibitor used at low "boosting" doses in many antiretroviral combinations to improve the pharmacokinetics of co-administered protease inhibitors. All synthetic corticosteroids — including triamcinolone acetonide — are CYP3A4 substrates. Under normal circumstances, triamcinolone from an intraarticular injection is slowly absorbed systemically and undergoes rapid hepatic and intestinal CYP3A4-mediated clearance, limiting its systemic exposure to low levels with minimal HPA axis effect. In a patient on ritonavir, CYP3A4 is profoundly inhibited throughout the course of antiretroviral therapy. When triamcinolone is absorbed from the joint space depot over days to weeks, it cannot be adequately cleared — plasma concentrations rise to levels that produce full systemic glucocorticoid effects, equivalent to receiving prolonged high-dose oral corticosteroid therapy. The result is iatrogenic Cushing syndrome (weight gain, facial puffiness, striae, fatigue) combined with HPA axis suppression that leaves the patient with secondary adrenal insufficiency once the depot is exhausted, reflected by the near-zero morning cortisol. This same interaction has been documented with inhaled fluticasone, intranasal corticosteroids, epidural injections, and intrabursal injections in ritonavir-treated patients — any route of corticosteroid administration can be affected.

• Option A: Option A is incorrect because HIV-associated autoimmune adrenalitis is not triggered by intraarticular corticosteroid injection; autoimmune adrenalitis requires systemic immune-mediated destruction, not localized exposure.
• Option B: Option B is incorrect because intraarticular triamcinolone 40 mg does not routinely produce systemic levels equivalent to oral prednisone 40 mg/day in patients without CYP3A4 inhibition; the ritonavir interaction is the critical factor distinguishing this patient's outcome.
• Option C: Option C is incorrect because HIV infection does not upregulate CYP3A4 through PXR activation; ritonavir specifically inhibits CYP3A4, and the described "toxic reactive intermediate" accumulation is pharmacologically implausible.

ANSWER: C

Rationale:

This patient has secondary adrenal insufficiency from prolonged HPA axis suppression by excessive systemic triamcinolone — confirmed by a morning cortisol below 1 µg/dL. The management follows the same principles as any case of secondary adrenal insufficiency. Physiological-dose hydrocortisone (15 to 20 mg/day in divided doses — typically two-thirds in the morning and one-third in the afternoon to mimic the normal diurnal cortisol rhythm) replaces endogenous cortisol during the period of HPA axis suppression. Secondary adrenal insufficiency from exogenous corticosteroid exposure does not cause mineralocorticoid deficiency because the zona glomerulosa remains responsive to the renin-angiotensin-aldosterone system (RAAS) and continues to produce aldosterone independently of ACTH; fludrocortisone is therefore not required. Sick-day rules — doubling or tripling the hydrocortisone dose during intercurrent illness, surgery, or procedures — are essential education to prevent adrenal crisis. HPA recovery typically occurs over months with gradual tapering guided by morning cortisol measurements. Regarding antiretroviral management: changes to a stable, virologically suppressive HIV regimen should be made collaboratively with the HIV specialist, weighing the risks of viral rebound against the corticosteroid interaction.

• Option A: Option A is incorrect because abruptly discontinuing a virologically effective antiretroviral regimen risks HIV viral rebound and resistance development; furthermore, CYP3A4 enzyme induction takes days to weeks after inducing medications are started, and does not occur within 72 hours of removing an inhibitor.
• Option B: Option B is incorrect because the morning cortisol of less than 1 µg/dL is itself diagnostic of severe adrenal insufficiency — values below approximately 3 µg/dL do not require ACTH stimulation testing for confirmation, and withholding treatment while performing confirmatory testing in a symptomatic patient with near-undetectable cortisol is clinically inappropriate.
• Option D: Option D is incorrect because the cause of HPA suppression was excess triamcinolone from the ritonavir interaction; administering further triamcinolone — even at lower doses — in a patient on ritonavir would perpetuate the very mechanism that caused the problem and would continue to suppress the HPA axis rather than allowing it to recover.

ANSWER: A

Rationale:

In a patient on ritonavir-based antiretroviral therapy who requires an inhaled corticosteroid, the selection must account for CYP3A4 dependency of the corticosteroid's systemic clearance. Fluticasone propionate is highly problematic in this context: it is almost entirely dependent on CYP3A4 for systemic metabolism, and case reports and pharmacokinetic studies have documented up to 350-fold increases in systemic fluticasone exposure in patients on ritonavir — producing iatrogenic Cushing syndrome and adrenal suppression, as this patient experienced from an intraarticular route. Beclomethasone dipropionate follows a fundamentally different metabolic pathway: it is converted by esterases within the lung tissue to beclomethasone-17-monopropionate, its pharmacologically active form, and this pathway is largely independent of CYP3A4. As a result, beclomethasone's systemic exposure is substantially less affected by ritonavir's CYP3A4 inhibition, and it is the preferred inhaled corticosteroid for patients on potent CYP3A4 inhibitors. Budesonide is intermediate in CYP3A4 dependence and has been associated with less severe (but still clinically significant) interactions with ritonavir than fluticasone.

• Option B: Option B is incorrect because the fluticasone-ritonavir interaction is clinically significant across the full range of inhaled doses, including 100 to 250 µg/day; there is no established safe dose threshold for fluticasone in patients on ritonavir, and the FDA and clinical guidelines specifically advise against this combination.
• Option C: Option C is incorrect because fluticasone furoate (used in once-daily inhalers) is also a CYP3A4 substrate; its ester group does not confer CYP3A4 resistance, and it shares the same interaction concern as fluticasone propionate in patients on potent CYP3A4 inhibitors.
• Option D: Option D is incorrect because not all inhaled corticosteroids carry equivalent CYP3A4 risk — beclomethasone specifically has a non-CYP3A4 pulmonary activation pathway that substantially reduces its systemic accumulation risk in the setting of CYP3A4 inhibition. Eliminating all inhaled corticosteroids is unnecessary and would leave asthma inadequately controlled.

ANSWER: B

Rationale:

The preventive principle from this case extends across all routes of corticosteroid administration. A common clinical misconception is that inhaled, topical, or intraarticular corticosteroids are "local" treatments with negligible systemic absorption and therefore safe in patients on CYP3A4 inhibitors. This case demonstrates precisely why that assumption is dangerous. Under CYP3A4 inhibition by ritonavir, any corticosteroid absorbed systemically — even in small amounts — cannot be adequately cleared, and plasma levels rise to pharmacologically active, potentially toxic concentrations over time. This applies to inhaled fluticasone (well-documented, up to 350-fold exposure increase), intraarticular triamcinolone (as in this case), epidural methylprednisolone, intranasal fluticasone, and topical corticosteroids under occlusion. The clinical obligation is to check for CYP3A4 inhibitor use before prescribing any corticosteroid by any route, and to select the lowest-CYP3A4-dependency corticosteroid for the clinical indication.

• Option A: Option A is incorrect because the interaction is not limited to intraarticular injection — it affects all routes of corticosteroid administration that produce any systemic absorption. Characterizing intraarticular injection as the "only route that bypasses first-pass metabolism" is incorrect; inhaled, intranasal, and topical corticosteroids also bypass hepatic first-pass to varying degrees.
• Option C: Option C is incorrect because the CYP3A4 interaction is not restricted to fluorinated corticosteroids; prednisolone and hydrocortisone are also CYP3A4 substrates, and ritonavir does raise their plasma levels, though the magnitude of interaction varies by agent. The claim that non-fluorinated corticosteroids use "exclusively glucuronidation" and are CYP3A4-independent is pharmacologically inaccurate.
• Option D: Option D is incorrect because using rifampin (a potent CYP3A4 inducer) as a prophylactic measure around corticosteroid injections is not a clinical strategy — rifampin's CYP3A4 induction would also dramatically reduce the efficacy of the patient's antiretroviral medications, risking HIV viral rebound and resistance development.

ANSWER: A

Rationale:

The pre-infusion serum urate measurement is the cornerstone of pegloticase safety monitoring, and understanding its role requires understanding the dominant safety concern: anti-drug antibody (ADA) formation. Approximately 40 to 50% of patients treated with pegloticase develop antibodies against the porcine uricase protein and/or the polyethylene glycol (PEG) moiety. When ADA form, they bind pegloticase and accelerate its clearance, reducing its circulating half-life and abolishing its uricase activity. The consequence is that serum urate, which initially fell to near-zero levels with effective treatment, begins to rise as the drug is cleared before the next infusion. A pre-infusion serum urate above 6 mg/dL during treatment is therefore the established surrogate marker for ADA-mediated loss of response. The critical safety implication is that the infusion must be held — not given — when the pre-infusion urate rises above 6 mg/dL, because patients with high ADA titers who receive the next infusion are at dramatically elevated risk of anaphylaxis and serious infusion reactions from ADA-antigen immune complex formation. Co-administered methotrexate reduces ADA formation and improves the proportion of patients who maintain response, but monitoring is required throughout.

• Option B: Option B is incorrect because pegloticase reduces serum urate to near-zero levels regardless of dietary purine intake — its enzymatic conversion of uric acid to allantoin is not overcome by normal dietary variation; a rising pre-infusion urate reflects drug clearance from ADA, not dietary factors.
• Option C: Option C is incorrect because the decision to discontinue prophylactic colchicine is based on the duration of ULT and crystal dissolution progress, not on a specific serum urate threshold; the pre-infusion measurement serves the ADA surveillance function, not colchicine discontinuation decision-making.
• Option D: Option D is incorrect because there is no FDA REMS threshold requiring dose reduction for low serum urate levels; allantoin nephropathy from near-zero serum urate is not a recognized clinical concern with pegloticase, and the monitoring protocol exists to detect ADA-mediated loss of response and prevent anaphylaxis, not to prevent overresponse.

ANSWER: D

Rationale:

The pre-infusion serum urate of 7.8 mg/dL — a dramatic rise from consistently below 1 mg/dL over the prior six infusions — is unambiguous evidence of anti-drug antibody (ADA) formation with antibody-mediated pegloticase clearance. The clinical protocol established for pegloticase is explicit: a pre-infusion serum urate above 6 mg/dL is the threshold for stopping treatment, not for continuing with premedication or confirming on repeat. The reason this threshold is a stopping signal rather than a monitoring signal is the safety risk: patients with high-titer ADA who receive a subsequent pegloticase infusion are at dramatically elevated risk of serious infusion reactions — anaphylaxis, urticaria, angioedema, hemodynamic instability — because the injected pegloticase forms immune complexes with circulating ADA, triggering complement activation and mast cell degranulation. This risk cannot be adequately mitigated by premedication alone. The infusion must be held regardless of how well the patient feels, because the absence of symptoms before the infusion does not predict what will occur during it.

• Option A: Option A is incorrect because the monitoring protocol for pegloticase does not require two consecutive elevated values before holding; a single pre-infusion urate above 6 mg/dL during treatment is itself the stopping criterion, precisely because administering the next infusion with confirmed ADA is dangerous.
• Option B: Option B is incorrect because premedication with antihistamines and corticosteroids reduces the severity of mild infusion reactions but does not adequately protect against the serious anaphylaxis risk associated with ADA-mediated immune complex reactions; continuing infusions with confirmed ADA is not the recommended approach regardless of premedication.
• Option C: Option C is incorrect for the same reason as Option A — a 48-hour recheck with a two-measurement rule is not the established clinical protocol; the single elevated pre-infusion urate at this magnitude, in a patient who had near-zero values for six consecutive infusions, is diagnostically unambiguous for ADA formation.

ANSWER: B

Rationale:

The temporal relationship between stopping methotrexate and the loss of pegloticase response illuminates the immunological mechanism precisely. Methotrexate was co-administered specifically to suppress the adaptive immune response against pegloticase's foreign protein components — the porcine uricase and the polyethylene glycol moiety. This suppression requires ongoing immunosuppression throughout the pegloticase course, because the patient's immune system is repeatedly exposed to pegloticase antigen at every biweekly infusion. When methotrexate was stopped three weeks before the seventh infusion, the immunological brake was removed. Without ongoing T-cell suppression, the immune system — which had been restrained but not permanently tolerized — was able to develop an antibody response against pegloticase antigen. By the time of the seventh pre-infusion measurement, sufficient anti-drug antibodies (ADA) had formed to accelerate pegloticase clearance, abolishing uricase activity and allowing serum urate to rise from near zero to 7.8 mg/dL. This case reinforces the importance of maintaining methotrexate throughout the planned pegloticase course without interruption; nausea should have been managed (with folate supplementation, dose adjustment, or antiemetics) rather than by stopping the drug.

• Option A: Option A is incorrect because methotrexate does not inhibit pegloticase enzymatic activity; its mechanism is immunological through DHFR (dihydrofolate reductase) inhibition in lymphocytes, not competitive binding at the uricase substrate site.
• Option C: Option C is incorrect because stopping methotrexate does not cause CYP3A4 induction; methotrexate does not affect CYP3A4 expression, and pegloticase is not metabolized by CYP3A4 (it is a large protein therapeutic cleared through the reticuloendothelial system).
• Option D: Option D is incorrect because allantoinase is a mammalian enzyme that converts allantoin to allantoate in organisms that have this pathway; humans do not have functional allantoinase activity. Allantoin does not undergo reverse conversion to uric acid, and product inhibition of uricase by allantoin is not a clinically relevant mechanism.

ANSWER: C

Rationale:

This patient has tophaceous gout, and the serum urate target for patients with visible tophi — or those with frequent attacks (≥3 per year) or urate-related joint damage — is <5 mg/dL (300 µmol/L) rather than the standard <6 mg/dL. The pharmacological rationale is thermodynamic: monosodium urate crystal dissolution requires that the surrounding extracellular urate concentration fall below the equilibrium solubility of the crystals. Reducing serum urate to <5 mg/dL creates a substantially steeper concentration gradient between the crystal depot and the extracellular fluid than maintaining it at 5.5 or 5.8 mg/dL, accelerating the rate of crystal dissolution and tophus volume reduction. Regarding ULT options for this patient: previous allopurinol inadequacy should be re-evaluated — if he was not optimally dosed or if dose escalation was limited by prior side effects that can now be managed differently, re-titration is appropriate. Combination therapy with probenecid (adding a uricosuric mechanism to XO inhibition) is an established option in patients not achieving target on monotherapy, provided there are no contraindications (normal renal function, no aspirin use, no nephrolithiasis history). Pegloticase re-initiation with more robust immunosuppression co-administration is a guideline-endorsed option for selected patients, though not all patients with prior ADA formation will respond to re-initiation.

• Option A: Option A is incorrect because tophi are not merely cosmetic; they represent large crystal deposits that can erode joints, damage tendons, limit function, and serve as ongoing sources of crystal shedding. The <5 mg/dL target specifically applies to tophaceous disease and is guideline-recommended.
• Option B: Option B is incorrect because re-initiating pegloticase in a patient with confirmed ADA formation is not straightforward dose escalation; patients who developed ADA may have difficulty responding to re-initiation, and the approach would require careful clinical evaluation and typically involves a "wash-in" period with immunosuppression rather than simply increasing methotrexate dose from the prior course.
• Option D: Option D is incorrect because serum urate does not remain low after pegloticase discontinuation — the drug's uricase activity was entirely responsible for the reduced urate levels, and without ongoing drug therapy, urate production and accumulation resume. Crystal dissolution that occurred during treatment is permanent, but new crystal formation and tophus regrowth will occur if serum urate is not controlled with ongoing ULT.

ANSWER: C

Rationale:

The diagnostic key in this case is the serum CK of 62 U/L — completely normal despite significant proximal muscle weakness. This finding is the strongest laboratory discriminator between steroid myopathy and inflammatory myopathies. Inflammatory myopathies (polymyositis, dermatomyositis, necrotizing myopathy) produce weakness through immune-mediated muscle fiber necrosis, which releases cytoplasmic enzymes — creatine kinase in particular — into the circulation. In active polymyositis, CK is typically elevated 10-fold or more above the upper limit of normal. In steroid myopathy, the mechanism is glucocorticoid receptor-mediated transcriptional suppression of muscle protein synthesis combined with upregulation of the ubiquitin-proteasome degradation pathway, producing selective type II (fast-twitch) fiber atrophy without fiber membrane disruption or necrosis. No CK is released, so serum CK remains normal. The additional clinical context supporting steroid myopathy: two years of prednisone at 10 mg/day, consistently normal ESR excluding active PMR inflammation, onset of weakness without pain or stiffness (PMR relapse characteristically presents with morning stiffness and proximal aching, not painless weakness), and symmetric gradual progression.

• Option A: Option A is incorrect because PMR characteristically presents with proximal aching, stiffness, and pain — not painless weakness. PMR does not produce the isolated painless proximal motor weakness pattern described; a CK-negative painless proximal weakness syndrome in a patient on long-term corticosteroids is steroid myopathy until proven otherwise.
• Option B: Option B is incorrect because while paraneoplastic myopathy should be considered in the broader differential, the most parsimonious explanation for painless proximal weakness with normal CK in a patient on long-term corticosteroids is steroid myopathy; paraneoplastic evaluation would be appropriate if steroid dose reduction does not improve the weakness.
• Option D: Option D is incorrect because corticosteroids do not cause hypothyroidism through TSH suppression at standard doses; while corticosteroids can transiently suppress TSH at high doses, this is not the mechanism for chronic steroid myopathy, and hypothyroid myopathy would present with additional features of hypothyroidism not described here.

ANSWER: B

Rationale:

The management of steroid myopathy follows directly from its pathophysiology. Steroid myopathy is caused by glucocorticoid receptor (GR)-mediated transcriptional effects in skeletal muscle: GR activation suppresses Wnt/beta-catenin and IGF-1/PI3K/mTOR signaling (reducing protein synthesis) while upregulating FoxO transcription factors and the ubiquitin-proteasome system (increasing protein degradation). The net result is selective type II fiber atrophy that progresses as long as the corticosteroid stimulus continues. The therapeutic corollary is clear: reducing the corticosteroid dose reduces the GR-mediated transcriptional burden on muscle, allowing protein synthesis to resume and fiber atrophy to recover over weeks to months. In a patient with PMR who requires some corticosteroid for disease control, the target is the minimum dose that maintains disease remission (confirmed by symptom control and normal ESR). If a particular fluorinated corticosteroid (dexamethasone, triamcinolone) is being used, switching to a non-fluorinated agent (prednisolone) at an equivalent anti-inflammatory dose may reduce myopathic risk, as fluorinated agents are generally associated with higher myopathic potential. Physical therapy to maintain muscle strength and functional capacity during recovery is an important adjunct.

• Option A: Option A is incorrect because increasing prednisone would worsen steroid myopathy — the cause of the myopathy is the corticosteroid itself, and dose escalation intensifies GR-mediated muscle fiber atrophy. There is no paradoxical anti-inflammatory benefit of higher doses for steroid myopathy.
• Option C: Option C is incorrect because hydroxychloroquine does not have equivalent anti-inflammatory efficacy to prednisone for PMR and is not an established treatment for PMR; abrupt prednisone discontinuation after two years at 10 mg/day would also risk adrenal insufficiency.
• Option D: Option D is incorrect because creatine supplementation has not been shown to reverse steroid myopathy in clinical trials; the mechanism of steroid myopathy is not creatine kinase suppression, and creatine supplementation is not a guideline-endorsed treatment for this condition.

ANSWER: D

Rationale:

This is the classic three-way differential during corticosteroid tapering: PMR relapse, corticosteroid withdrawal syndrome, and secondary adrenal insufficiency. The normal inflammatory markers (ESR 12 mm/hr, CRP <0.5 mg/L) make PMR relapse the least likely explanation — ESR and CRP are highly sensitive for active PMR inflammation and are not routinely suppressed to normal levels by prednisone 5 mg/day. The clinical picture of somatic symptoms (fatigue, arthralgias, myalgia, nausea) without disease-specific joint inflammation points toward either withdrawal syndrome or adrenal insufficiency. Corticosteroid withdrawal syndrome reflects physiological adaptation to supraphysiological glucocorticoid receptor activation — when the dose is reduced, tissues experience relative deficiency even if the HPA axis is intact. Adrenal insufficiency reflects genuine HPA suppression with inadequate cortisol production. The morning cortisol of 11 µg/dL is critical to interpret correctly: it falls in the indeterminate range between approximately 3 µg/dL (strongly consistent with adrenal insufficiency) and 18 µg/dL (normal for an 8 AM measurement). Values in this range cannot reliably distinguish withdrawal syndrome from adrenal insufficiency — the ACTH stimulation test is required. A peak cortisol of ≥18 µg/dL after cosyntropin administration confirms intact adrenal reserve, supporting withdrawal syndrome as the diagnosis and slower taper as the management. A subnormal peak confirms adrenal insufficiency requiring management with hydrocortisone.

• Option A: Option A is incorrect because inflammatory markers are not rendered uniformly uninformative by prednisone 5 mg/day; ESR and CRP remain sensitive markers for PMR activity at this dose level, and their normality reliably argues against active disease.
• Option B: Option B is incorrect because a morning cortisol of 11 µg/dL does not confirm adrenal insufficiency; only values below approximately 3 µg/dL are strongly diagnostic without further testing. The 18 µg/dL threshold refers to the lower limit of a normal morning cortisol — values between 3 and 18 µg/dL are indeterminate and require ACTH stimulation testing.
• Option C: Option C is incorrect because vitamin D deficiency does not produce a withdrawal syndrome pattern following corticosteroid dose reduction, and this scenario has no clinical features specific to vitamin D deficiency; the timing of symptoms directly after the dose reduction points clearly to a corticosteroid-related mechanism.

ANSWER: A

Rationale:

Structured monitoring for patients on long-term systemic corticosteroids reflects the breadth of organ systems affected by glucocorticoid excess and the preventive interventions available for each. For patients on prednisone ≥7.5 mg/day for ≥3 months — the ACR threshold for bisphosphonate prophylaxis consideration — the monitoring framework includes: bone density (DEXA at baseline and every one to two years to detect GIOP progression and guide bisphosphonate therapy decisions); metabolic monitoring (fasting blood glucose and HbA1c at baseline and every three to six months — with the important caveat that fasting glucose underestimates steroid-induced hyperglycemia, so postprandial monitoring is more sensitive); cardiovascular monitoring (blood pressure at every visit to detect steroid-induced hypertension; fasting lipid profile annually for steroid-induced dyslipidemia); renal and electrolyte monitoring (serum potassium and creatinine periodically, particularly in patients also on diuretics or ACE inhibitors/ARBs); and ophthalmologic review annually for posterior subcapsular cataracts (cumulative dose/duration dependent, largely irreversible) and intraocular pressure (corticosteroid-induced glaucoma, reversible). In pediatric patients, growth velocity monitoring is added.

• Option B: Option B is incorrect because monitoring is required even before fractures occur — the purpose of DEXA in GIOP is preventive surveillance, and bisphosphonate initiation is based on dose/duration criteria, not on fracture occurrence; monitoring should continue throughout therapy to guide management decisions.
• Option C: Option C is incorrect because the monitoring obligations apply at prednisone ≥7.5 mg/day, not just ≥10 mg/day, and clinically significant toxicities — including GIOP, steroid-induced hyperglycemia, and cataracts — occur at these lower doses with sufficient duration.
• Option D: Option D is incorrect because routine HPA axis testing (every three months) is not the primary monitoring obligation and is not standard-of-care for asymptomatic patients on stable corticosteroid doses; HPA testing is performed when dose reduction is planned or when symptoms raise concern for adrenal insufficiency, not as a routine quarterly test. The bone, metabolic, cardiovascular, and ophthalmic monitoring described in option A are the established structured obligations.

ANSWER: D

Rationale:

This patient presents with one of the most pharmacologically constrained clinical scenarios in acute gout management. Systematically reviewing each standard option: NSAIDs are doubly contraindicated — the prior GI bleed on indomethacin represents a significant history of NSAID gastropathy, and the creatinine clearance of 28 mL/min (CKD stage 4 level) combined with cyclosporine-induced renal vasoconstriction creates severe risk for NSAID-mediated AKI and graft dysfunction. Colchicine is generally contraindicated with cyclosporine: cyclosporine is a potent inhibitor of both CYP3A4 and P-glycoprotein, dramatically raising colchicine plasma concentrations to potentially life-threatening levels. Additionally, colchicine requires dose adjustment at eGFR <30 mL/min and is contraindicated at eGFR <15 mL/min. Intraarticular corticosteroids are impractical for polyarticular disease involving both ankles and the wrist — three separate injections are required, increasing procedural risk, and joint-space injection in immunosuppressed patients carries infection risk. Systemic corticosteroids — oral prednisone 30 to 40 mg/day for five to seven days — are the remaining appropriate option. The physician must balance adding corticosteroid to a patient already on immunosuppression, but the short course is generally tolerated and provides effective anti-inflammatory treatment for polyarticular gout. If corticosteroids are also problematic (e.g., poorly controlled diabetes), IL-1 inhibitors (anakinra) provide a targeted alternative.

• Option A: Option A is incorrect because colchicine is generally contraindicated with cyclosporine at any dose — there is no established safe low-dose threshold for the colchicine-cyclosporine combination, and fatal toxicity has been documented at doses comparable to the low-dose regimen.
• Option B: Option B is incorrect because a creatinine clearance of 28 mL/min combined with cyclosporine-induced afferent arteriolar vasoconstriction represents a severe contraindication to NSAIDs; short-course NSAID use in this setting carries significant risk of acute graft injury, and prior GI bleed on an NSAID makes the GI risk also unacceptably high.
• Option C: Option C is incorrect because intraarticular corticosteroid injection in three separate joints is procedurally impractical for polyarticular disease and carries disproportionate infection risk in an immunosuppressed transplant recipient; systemic therapy is more appropriate. The claim that cyclosporine-corticosteroid interaction does not apply to intraarticular injections is also incorrect — systemic absorption from intraarticular depots can still produce significant drug interaction in the setting of CYP3A4 inhibition.

ANSWER: A

Rationale:

Two distinct pharmacological principles are integrated in this question. The first is ULT timing: regardless of how high the serum urate is, ULT should not be initiated during or immediately after an acute attack. Initiating allopurinol during an acute attack causes a rapid drop in serum urate that destabilizes urate crystal deposits, promotes crystal shedding into the joint space, and re-activates the NLRP3 inflammasome in a joint that is already acutely inflamed — worsening and prolonging the attack. Current guidelines recommend waiting until the acute attack has fully resolved (typically two to four weeks) before starting ULT, then co-prescribing prophylactic colchicine or an alternative to suppress crystal shedding flares during the initiation phase. The second principle is the allopurinol-azathioprine interaction: allopurinol inhibits xanthine oxidase (XO), the same enzyme responsible for metabolizing azathioprine to inactive metabolites. When allopurinol is co-administered with azathioprine, azathioprine plasma levels rise dramatically, causing severe bone marrow suppression and potentially fatal myelotoxicity. This interaction is one of the most dangerous in pharmacology. However, this patient is on mycophenolate — not azathioprine — for immunosuppression. Mycophenolate acts through IMPDH (inosine monophosphate dehydrogenase) inhibition and does not interact with allopurinol through XO. Allopurinol is therefore appropriate and safe in this patient, started at a low dose (consistent with the creatinine clearance-based starting rule) after attack resolution.

• Option B: Option B is incorrect because the degree of hyperuricemia does not change the fundamental principle that ULT initiation during an acute attack worsens inflammation through crystal shedding; there is no serum urate threshold above which immediate ULT initiation is indicated during an acute attack.
• Option C: Option C is incorrect because the CARES trial finding of higher cardiovascular mortality applies to patients with established CVD broadly; the statement that it does not apply to transplant patients without prior cardiovascular disease may be partially true, but febuxostat is not universally preferred over allopurinol in all transplant patients and is reserved for allopurinol failure or intolerance.
• Option D: Option D is incorrect because allopurinol can be used at a creatinine clearance of 28 mL/min — with careful dose starting (based on the CrCl-based rule) and monitoring; it is not contraindicated at this level of renal function. The absolute contraindication for colchicine is eGFR <15 mL/min, and probenecid is contraindicated at eGFR <30 mL/min, but allopurinol remains an option.

ANSWER: C

Rationale:

The pharmacokinetic rationale for the colchicine-cyclosporine contraindication applies regardless of the colchicine dose. Cyclosporine is a potent concurrent inhibitor of CYP3A4 (the primary hepatic enzyme responsible for colchicine oxidative metabolism) and P-glycoprotein (P-gp, the efflux transporter that limits intestinal absorption and facilitates biliary and renal colchicine elimination). When both pathways are inhibited simultaneously, colchicine plasma concentrations rise dramatically — by a factor reported in pharmacokinetic studies to be 2- to 4-fold or more even with single doses. At prophylactic doses intended to be taken daily for three to six months, sustained elevation of colchicine plasma levels creates cumulative risk for colchicine toxicity: neuromuscular toxicity, myopathy, peripheral neuropathy, and bone marrow suppression (pancytopenia). There is no established safe prophylactic dose of colchicine in patients on cyclosporine. Low-dose prednisone (5 to 10 mg/day) is recognized in ACR and EULAR gout guidelines as a second-line prophylactic option when both colchicine and NSAIDs are contraindicated — exactly this patient's situation. His immunosuppressive regimen already includes mycophenolate, and adding low-dose prednisone for three to six months, while requiring glucose and blood pressure monitoring, is clinically feasible.

• Option A: Option A is incorrect because cyclosporine-induced renal insufficiency does not prevent ULT-associated flares; crystal shedding is driven by urate thermodynamics and NLRP3 inflammasome activation that are independent of renal prostaglandin status. Patients with CKD on ULT do experience prophylaxis-requiring flares.
• Option B: Option B is incorrect because while cyclosporine inhibits calcineurin in T cells, it does not reliably suppress the NLRP3 inflammasome in synovial macrophages and neutrophils sufficiently to prevent acute gout attacks; cyclosporine-treated patients commonly develop and suffer from acute gout attacks.
• Option D: Option D is incorrect because there is no pharmacokinetically established safe colchicine dose threshold in patients on cyclosporine; the interaction affects the entire dose range through simultaneous CYP3A4 and P-gp inhibition. The claim that doses below 1 mg/day are below the interaction threshold is not supported by pharmacokinetic data or clinical evidence.

ANSWER: B

Rationale:

This question integrates two separate pharmacological principles. The serum urate target: for patients with visible tophi, the ACR and EULAR guidelines specify a target of <5 mg/dL (300 µmol/L) rather than the standard <6 mg/dL. The lower target creates a steeper thermodynamic gradient favoring crystal dissolution at the tophus surface, accelerating tophus volume reduction in patients with substantial crystal burden. The probenecid assessment requires checking each contraindication systematically. First, renal function: probenecid's uricosuric efficacy requires adequate tubular urine flow and filtration to generate sufficient urinary urate excretion; it becomes progressively less effective as eGFR falls, and the clinically accepted threshold for adequate efficacy is approximately eGFR ≥30 mL/min (or creatinine clearance ≥30 mL/min). At 28 mL/min, the patient is below this threshold — probenecid is unlikely to produce meaningful urate-lowering. Second, aspirin 81 mg/day: low-dose aspirin (≤325 mg/day) competitively inhibits the URAT1 and GLUT9 transporters at low salicylate concentrations, blocking probenecid's uricosuric mechanism and rendering it ineffective. This patient takes aspirin for cardiovascular protection, which cannot be discontinued. The appropriate management is continued allopurinol dose titration — doses of 200 to 300 mg/day may be achievable with monitoring in this patient, and each dose increment may provide incremental urate lowering.

• Option A: Option A is incorrect because the serum urate target for tophaceous disease is <5 mg/dL, not <6 mg/dL; and probenecid is not appropriate at creatinine clearance 28 mL/min.
• Option C: Option C is incorrect because the aspirin-uricosuric interaction does occur at low cardiovascular prophylaxis doses (81 mg/day) — this is the clinically documented interaction. High-dose aspirin (≥3 g/day) paradoxically has its own uricosuric effect, but low-dose aspirin blocks the probenecid mechanism.
• Option D: Option D is incorrect because the accepted clinical threshold for probenecid efficacy is eGFR approximately ≥30 mL/min, not 20 mL/min as stated; and the aspirin interaction applies regardless of whether allopurinol is also being taken — aspirin blocks URAT1 regardless of co-administered agents.

ANSWER: B

Rationale:

This is a textbook presentation of severe colchicine toxicity from the clarithromycin-colchicine pharmacokinetic interaction. Colchicine's elimination depends on two parallel pathways: CYP3A4-mediated hepatic oxidative metabolism and P-glycoprotein (P-gp)-mediated efflux in the intestinal wall and biliary system. Clarithromycin is a potent inhibitor of both CYP3A4 and P-gp simultaneously. When co-administered with colchicine, clarithromycin reduces both colchicine's hepatic clearance and its intestinal efflux/elimination, causing plasma colchicine concentrations to rise substantially above the therapeutic range. At supratherapeutic concentrations, colchicine's mechanism — binding tubulin heterodimers and inhibiting microtubule polymerization — acts in tissues beyond its intended target (neutrophils and synovial cells). Bone marrow progenitor cells depend on microtubule-mediated mitotic spindle function for cell division; toxicity here produces myelosuppression and pancytopenia affecting all three cell lines (leukopenia, anemia, thrombocytopenia) as demonstrated by the CBC. Peripheral nerve axons require microtubule-mediated axonal transport; toxicity produces peripheral neuropathy. Skeletal muscle requires normal microtubule networks for myofibril function; toxicity produces myopathy. This neuromuscular-hematological triad is the pathognomonic presentation of severe colchicine toxicity and carries significant mortality if unrecognized.

• Option A: Option A is incorrect because clarithromycin is not a recognized cause of aplastic anemia at standard doses; the specific temporal relationship and the neuromuscular features alongside the cytopenias are characteristic of colchicine toxicity, not isolated bone marrow suppression.
• Option C: Option C is incorrect because clarithromycin does not bind or destabilize tubulin; it is a macrolide antibiotic that inhibits bacterial ribosomal protein synthesis and exerts no direct tubulin-binding pharmacodynamic effect in mammalian cells.
• Option D: Option D is incorrect because anti-tubulin autoantibody formation is not a mechanism of colchicine toxicity; colchicine toxicity is a direct pharmacological effect of supratherapeutic concentrations on microtubule function, not an immune-mediated process.

ANSWER: D

Rationale:

Severe colchicine toxicity is a medical emergency, and the immediate priority is removing the causative agents. Colchicine must be discontinued immediately — continuing the drug at any dose while toxicity is already manifest will perpetuate and worsen the multi-organ toxicity syndrome. Clarithromycin should also be discontinued or switched to an alternative antibiotic without CYP3A4 or P-gp inhibitory activity (azithromycin, for example, has significantly lower CYP3A4 inhibitory potency) to remove the pharmacokinetic driver of colchicine accumulation. The pneumonia requires continued treatment, and selecting an antibiotic that does not perpetuate the interaction is critical. Supportive care addresses the consequences of toxicity: leukopenia increases infection risk and patients require close monitoring for fever, signs of sepsis, and possible empirical antimicrobial broadening; anemia and thrombocytopenia may require transfusion support depending on clinical severity; renal function monitoring is important as colchicine has some renal toxicity at high levels. There is no specific antidote for colchicine toxicity — no reversal agent exists that is clinically available for this indication. Recovery depends on drug elimination and supportive care; the time course depends on the degree of accumulation and the rate of colchicine clearance once the drug and the inhibitor are discontinued.

• Option A: Option A is incorrect because folinic acid is used for methotrexate toxicity (bypassing DHFR inhibition) — it has no role in colchicine toxicity. Colchicine does not inhibit DHFR, and folinic acid does not reverse tubulin-binding toxicity or restore microtubule function.
• Option B: Option B is incorrect because dose reduction is not an appropriate response to established multi-organ toxicity; with CK-myopathy, peripheral neuropathy, and pancytopenia already manifest, continued colchicine administration at any dose is inappropriate. The toxic accumulation from CYP3A4/P-gp inhibition requires drug discontinuation, not dose reduction.
• Option C: Option C is incorrect because there is no FDA-approved colchicine-specific antibody fragment antidote; colchicoside Fab fragments are not a commercially available or regulatory-approved reversal agent. Digoxin immune Fab is the analogous product for digoxin toxicity, but no equivalent exists for colchicine.

ANSWER: C

Rationale:

In a patient with normal systemic corticosteroid requirements, the rifampin-corticosteroid CYP3A4 interaction that would be the primary concern in a corticosteroid-dependent patient is not the immediate issue. However, rifampin is a broad and potent CYP3A4 inducer that creates a wide range of drug interactions — it reduces plasma levels of virtually every CYP3A4-substrate medication, including numerous antibiotics, anticoagulants, antivirals, and immunosuppressants. For a patient with a complex medication history and gout, isoniazid is the cleaner choice: isoniazid does not significantly induce or inhibit CYP3A4 and creates far fewer drug interactions relevant to gout or general medical management. The LTBI treatment guidelines recommend isoniazid for nine months as the standard long-course option or rifampin for four months as the shorter option; both have comparable efficacy. In patients where drug interactions are a concern, isoniazid's narrower interaction profile makes it preferable. There is no indication from this case that the patient cannot tolerate isoniazid or has a contraindication to it.

• Option A: Option A is incorrect because prior colchicine toxicity does not impair hepatic CYP3A4 capacity in a way that requires isoniazid preference; colchicine toxicity in this case was pharmacokinetic (drug accumulation from CYP3A4/P-gp inhibition), not hepatotoxic (structural liver damage).
• Option B: Option B is incorrect because rifampin does not inhibit OAT3-mediated oxypurinol secretion in a clinically significant way that would cause oxypurinol accumulation and allopurinol hypersensitivity; rifampin's CYP3A4 induction actually increases (not decreases) drug clearance, and oxypurinol is primarily eliminated by renal filtration.
• Option D: Option D is incorrect because rifampin does not inhibit xanthine oxidase; XO inhibition is the mechanism of allopurinol itself. Rifampin is a bacterial RNA polymerase inhibitor and nuclear receptor CYP3A4 inducer with no XO inhibitory activity.

ANSWER: A

Rationale:

The prior colchicine toxicity in this patient was entirely pharmacokinetic in origin — caused by clarithromycin's dual inhibition of CYP3A4 and P-gp, which raised colchicine plasma concentrations to toxic levels. The patient's colchicine pharmacokinetics are inherently normal; it was the drug interaction, not an intrinsic susceptibility to colchicine, that caused the toxicity. With the interaction removed — clarithromycin discontinued, no other CYP3A4/P-gp inhibitors in his current regimen — colchicine can be safely restarted at prophylactic doses. The essential prescribing check before any colchicine prescription is a review of the current and planned medication regimen for CYP3A4 inhibitors (azole antifungals, macrolide antibiotics, ritonavir, cyclosporine, diltiazem, verapamil) and P-gp inhibitors. With normal renal function and a clean medication list, colchicine 0.5 to 0.6 mg once or twice daily is appropriate prophylaxis and has a well-established safety record. The physician should also counsel the patient that if a macrolide antibiotic or other potent CYP3A4/P-gp inhibitor is prescribed in the future, colchicine must be held or the antibiotic must be selected from a non-interacting class.

• Option B: Option B is incorrect because colchicine is not permanently contraindicated after drug interaction-induced toxicity; permanent contraindication would be appropriate if the patient had an intrinsic idiosyncratic reaction to colchicine itself, but this toxicity was pharmacokinetic and entirely interaction-mediated. Re-exposure without the precipitating interaction is safe.
• Option C: Option C is incorrect because G6PD deficiency is not a recognized contraindication to colchicine; colchicine does not produce oxidative hemolysis and is not metabolized through a pathway that generates reactive oxygen species hazardous in G6PD-deficient patients. G6PD screening is required before dapsone, primaquine, and certain other agents — not before colchicine.
• Option D: Option D is incorrect because ABCB1 pharmacogenomic testing is not a standard clinical requirement before prescribing colchicine; while ABCB1 variants may theoretically influence P-gp expression, routine ABCB1 genotyping before colchicine is not guideline-recommended practice, and the prior toxicity was explained by the clarithromycin drug interaction — pharmacogenomic testing is not indicated.

ANSWER: C

Rationale:

The three-marker HBV serological panel (HBsAg, anti-HBc, anti-HBs) defines distinct risk categories for reactivation under immunosuppression, and the pattern in this case represents one of the highest-risk scenarios among HBsAg-negative patients. HBsAg-negative, anti-HBc-positive, anti-HBs-negative — termed "isolated anti-HBc positivity" — reflects past HBV infection in which the natural anti-HBs response has waned over time or was never mounted robustly. Critically, anti-HBc positivity confirms that the patient has been genuinely infected with HBV (not merely vaccinated — vaccination produces anti-HBs only, never anti-HBc), and hepatocytes from a previous infection retain viral cccDNA (covalently closed circular DNA) in their nuclei as a transcriptional template that can persist for decades. The absence of anti-HBs means there is no residual humoral immune protection against HBV reactivation. Under the combination of mycophenolate (which depletes lymphocyte purine pools and suppresses both T and B cell function) and prednisone 40 mg/day, the immune surveillance against reactivating cccDNA is substantially impaired. For high-level immunosuppression with anti-HBc-positive patients — particularly those lacking anti-HBs — antiviral prophylaxis with a high-barrier-to-resistance nucleotide analogue (entecavir 0.5 mg/day or tenofovir disoproxil fumarate 300 mg/day) is recommended, continued for 12 months after immunosuppression is discontinued to cover the recovery period.

• Option A: Option A is incorrect because anti-HBc is never produced by HBV vaccination; the vaccine (composed of recombinant HBsAg) generates anti-HBs only. Anti-HBc positivity specifically indicates natural HBV infection.
• Option B: Option B is incorrect because HBsAg-negative, anti-HBc-positive, anti-HBs-negative represents past resolved infection with reactivation risk — not active chronic occult infection requiring immediate antiviral therapy before immunosuppression. The distinction is important: active chronic HBV requires HBsAg positivity or detectable HBV DNA.
• Option D: Option D is incorrect because lupus-associated polyclonal B-cell activation does not produce false-positive anti-HBc results; anti-HBc is a specific antibody to HBV core antigen and its presence in a patient from an HBV-endemic region (East Asia) reliably indicates prior HBV infection.

ANSWER: A

Rationale:

The preference for entecavir and tenofovir over lamivudine for prolonged HBV prophylaxis in immunosuppressed patients is grounded in the concept of genetic barrier to resistance. Lamivudine inhibits HBV reverse transcriptase, but its binding site at the YMDD motif of the polymerase is particularly susceptible to resistance mutations. The most common resistance mutation substitutes isoleucine or valine for methionine at codon 204 (rtM204I/V), producing lamivudine-resistant HBV strains. The rate of lamivudine resistance in patients with chronic HBV treated for two or more years approaches 60 to 70%. In the context of prophylaxis during extended immunosuppression — where the patient may be on therapy for years — resistance emergence is a genuine clinical risk: lamivudine-resistant HBV reactivation can occur, is harder to treat, and may produce severe hepatitis. Entecavir is a cyclopentyl guanosine analogue with a high genetic barrier to resistance — requiring multiple simultaneous mutations for resistance to emerge; resistance is extremely rare in treatment-naive patients. Tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) similarly have very high resistance barriers with no documented resistance mutations in clinical use. For patients requiring prolonged prophylaxis, these high-barrier agents are the standard of care.

• Option B: Option B is incorrect because none of the nucleotide analogues — lamivudine, entecavir, or tenofovir — directly degrades cccDNA in the hepatocyte nucleus. They all act at the cytoplasmic reverse transcriptase step to suppress new viral replication, and none has a mechanism that directly eliminates cccDNA.
• Option C: Option C is incorrect because the FDA approval distinctions described do not correspond to the actual regulatory landscape; the choice between agents is based on resistance barrier and clinical trial data, not on specific prophylaxis-versus-treatment regulatory divisions that exclude tenofovir and lamivudine from prophylaxis.
• Option D: Option D is incorrect because lamivudine for HBV does not require three-times-daily dosing; it is administered once daily for HBV (300 mg/day), as are entecavir and tenofovir. Dosing frequency equivalence makes adherence differences irrelevant as the distinguishing factor.

ANSWER: D

Rationale:

Breakthrough HBV reactivation during antiviral prophylaxis — defined as rising HBV DNA in a patient on antiviral therapy — requires a structured clinical response. The first step is always to assess adherence: subtherapeutic drug levels from missed doses are the most common cause of breakthrough, and this must be established before attributing the finding to drug resistance. If adherence is confirmed, quantitative HBV DNA testing and genotypic resistance testing should be performed to determine whether resistance mutations are present. While entecavir resistance is uncommon in treatment-naive patients, it can occur — particularly in patients who had prior lamivudine exposure (the rtM204V/I mutations from lamivudine resistance are necessary precursors to entecavir resistance). If resistance is identified, switching to or adding tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF) is appropriate, as tenofovir retains activity against entecavir-resistant HBV strains through a different resistance profile. A hepatologist should be involved for this degree of virological and biochemical activity. Critically, immunosuppression should not be abruptly discontinued: rapid removal of immunosuppression in a patient with HBV reactivation can trigger immune reconstitution inflammatory syndrome (IRIS) — a massive immune-mediated attack on HBV-infected hepatocytes as T-cell function is restored — producing a hepatitis flare far more severe than the breakthrough reactivation itself.

• Option A: Option A is incorrect because ALT elevation with detectable HBV DNA during antiviral prophylaxis is not a normal or expected "immune reconstitution" response; it represents virological breakthrough that requires investigation.
• Option B: Option B is incorrect because ribavirin has no established efficacy against HBV; it is used for hepatitis C and some other viral infections. Entecavir-resistant HBV is treated with tenofovir, not ribavirin.
• Option C: Option C is incorrect because abruptly stopping all immunosuppression in a patient with lupus nephritis risks disease flare, and pegylated interferon-alpha is contraindicated in the context of active lupus nephritis — its immunostimulatory effects can precipitate lupus flares and are not used in immunosuppressed patients with significant autoimmune disease.

ANSWER: B

Rationale:

The recommended duration of antiviral prophylaxis after immunosuppression ends — 12 months — is derived from the biology of immune reconstitution. When immunosuppression is stopped, the immune system does not recover instantaneously. B-cell function, T-helper cell activity, and HBV-specific humoral immunity (anti-HBs production capability) take months to recover to normal levels. During this recovery period, residual hepatocyte cccDNA remains capable of transcriptional reactivation if viral surveillance is insufficient. The 12-month post-immunosuppression duration is designed to cover the full period of immune reconstitution: by 12 months after stopping standard immunosuppressants, most patients have recovered sufficient adaptive immune function to independently control low-level cccDNA activity. For patients who received anti-CD20 therapy (rituximab), the recommended duration is 18 to 24 months because B-cell reconstitution takes substantially longer following rituximab-mediated B-cell depletion. After prophylaxis is stopped, periodic HBV DNA and ALT monitoring for 12 months is recommended to detect late reactivation.

• Option A: Option A is incorrect because immune recovery after mycophenolate and corticosteroid discontinuation takes months, not 48 to 72 hours; the 12-month prophylaxis window specifically addresses the vulnerability period during immune reconstitution. Stopping antiviral therapy simultaneously with immunosuppression would leave the patient unprotected during the highest-risk period.
• Option C: Option C is incorrect because antiviral prophylaxis is not required indefinitely in all anti-HBc-positive patients after immunosuppression; the goal is to cover the period of immune vulnerability, after which most patients' reconstituted immune systems can contain residual cccDNA. Indefinite therapy is appropriate for patients with active chronic HBV or with severely impaired immunity, not for the general prophylaxis population.
• Option D: Option D is incorrect because undetectable HBV DNA during antiviral therapy does not confirm cccDNA silencing — it confirms viral suppression by the drug. Once entecavir is stopped, the cccDNA transcriptional template remains and can reactivate if immune surveillance is inadequate; stopping based on viral load during therapy would not protect against reactivation after stopping.